Mechanism and management of AKT inhibitor-induced hyperglycemia. - Wikidata - wikimedia - TriplyDB

Mechanism and management of AKT inhibitor-induced hyperglycemia.

Mechanism and management of AKT inhibitor-induced hyperglycemia.

http://www.wikidata.org/entity/Q46178252

about

Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum Maximising the potential of AKT inhibitors as anti-cancer treatments Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)Computer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunities GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt.Novel inhibitors of AKT: assessment of a different approach targeting the pleckstrin homology domain.An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo.The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors Relieving autophagy and 4EBP1 from rapamycin resistance.Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer Clinical development of phosphatidylinositol-3 kinase pathway inhibitors DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.Akt inhibitors in clinical development for the treatment of cancer.The Akt signaling pathway: an emerging therapeutic target in malignant melanoma.Fasting regulates EGR1 and protects from glucose- and dexamethasone-dependent sensitization to chemotherapy.Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials.Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors Cell survival and metastasis regulation by Akt signaling in colorectal cancer The use of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor.Targeting the PI3K-AKT-mTOR signaling network in cancer.A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors.Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies.Akt isoforms and glucose homeostasis - the leptin connection.The Biological Role of PI3K Pathway in Lung Cancer.Drug-Induced Hyperglycaemia and Diabetes.The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.Co-Managing Patients with Type 1 Diabetes and Cancer.Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview.Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity?Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.AKT/PKB Signaling: Navigating the Network.Past and current perspective on new therapeutic targets for Type-II diabetes.Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma Quantitation of glucose uptake in tumors by dynamic FDG-PET has less glucose bias and lower variability when adjusted for partial saturation of glucose transport.The power of FDG-PET to detect treatment effects is increased by glucose correction using a Michaelis constant.

P2860

Q26775379-A504FBD6-C1E4-4F6E-9EF8-80EEA648398B Q27009375-9EFF2009-B774-4677-AB2E-D682362DB32D Q27851722-7E4050D9-AB7A-4282-B607-3C21B865E4CD Q28072254-57DA0287-DAC0-4361-9F7D-74AD34141598 Q28080599-67894DD6-C1E4-4365-B492-E20EAA169646 Q28397537-44588B3D-68B4-42C2-A844-71412CF7CA27 Q33596707-B32A913A-0B2F-46FD-B11E-4B6F5FB326AD Q33882138-CA9483E4-08EB-4377-9D09-B5A1A18817A7 Q34329614-1022F84E-468F-438F-835B-4DA6E439514C Q34500544-5463F64D-571A-4981-B8F6-1B616217DEC0 Q34518245-675773E2-683A-4344-9034-D89C0452632A Q35051964-A606D1B7-87E2-420E-8C6E-176B709E18AF Q35096637-25AF6268-876E-42DC-9ACF-67EAA87109D5 Q35256618-BBFEEF4C-0858-40A7-815B-0F2DA07E300F Q35566234-9C15C982-73BE-4D5C-BB0B-103FC4F2591D Q35571896-EFA356C0-606D-4A19-B42B-CC34652D109D Q35628576-9AD65418-04BF-495C-9434-B58FAC746635 Q35911227-5DFC4410-90BE-44C1-82C0-C1E31D59FBA6 Q36328064-3673B9A5-148E-4CC5-8218-AB40A1044EB3 Q36443880-5488CF36-2FD3-49E1-9030-FBFA1C84FC1D Q36703783-B689017E-FC64-4F3D-8A96-B4F1EADE1CD8 Q36762858-C0CBAC2B-64B8-4E2C-8BC9-185E69BBB09F Q36938826-9966670F-BAA1-44AD-9FFC-3F83B57EF131 Q37167139-52A2ACC4-B872-4BED-AAFD-6370F4BD04C7 Q37353968-0337AB0F-1497-4AFD-9A72-7F9F79E998C9 Q37578324-41542409-8AB5-4739-BE84-61FE3BC81D99 Q37600837-59BDDA7D-5373-4031-8ED9-82A7E05DEE18 Q37800267-90867AFB-D73F-40D2-8168-A91C2989B3AE Q38166599-816818D4-DC4B-40CE-913F-E5EACA7DEE83 Q38586781-E01FB144-DD64-4192-A0D2-A1D3CA7EC169 Q38625610-421A3A22-41C1-470A-BFCB-D4714B53506A Q38869694-E5E89E88-B831-4710-996B-4CB8B0F60AD5 Q38989374-72A105E3-324F-4C18-959A-3ACF34F7C7ED Q39040854-13A09020-65E2-4366-8036-0E3FE943F3EE Q39098904-2FA14141-A4F4-4A7E-A4A7-30F128E8963D Q39255027-EC1989F8-A8CE-4ACD-B721-FE2B9420CD7B Q39349756-01745F96-515F-4390-B58E-928AC88E610F Q41838545-3E1E70BB-80E9-46CA-ABDB-F9F59E5E9C41 Q41858745-489848A5-5F3E-4C31-A6B6-1947D810D589 Q42424800-DED453D3-01EA-4D3B-AE5D-F40755DD809E

P2860

Mechanism and management of AKT inhibitor-induced hyperglycemia.

http://www.wikidata.org/entity/Q46178252

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Mechanism and management of AKT inhibitor-induced hyperglycemia.

@en

Mechanism and management of AKT inhibitor-induced hyperglycemia.

@nl

type

label

Mechanism and management of AKT inhibitor-induced hyperglycemia.

@en

Mechanism and management of AKT inhibitor-induced hyperglycemia.

@nl

prefLabel

Mechanism and management of AKT inhibitor-induced hyperglycemia.

@en

Mechanism and management of AKT inhibitor-induced hyperglycemia.

@nl

P1433

Q46178252-925FDC8E-F2DB-4B1E-870B-B19F02A2F013

P1476

Q46178252-F8A0994E-F848-486A-A6C7-FEEDE807898A

P2093

Q46178252-1E13D2A1-BF89-4318-8DB8-205C3A3C3276

Q46178252-42481E95-FE40-4428-95F4-59B7BDF59DC6

Q46178252-62A8491D-46B9-404B-AD9B-6AD653842250

Q46178252-8FC6E742-BDBD-4A0B-A6E6-4C7DD56A9F59

Q46178252-A0936D21-0C20-4124-B33C-78B78A029C6E

Q46178252-A5D59253-7127-4A2D-8104-F349E4D88218

Q46178252-B352C357-FC26-48BD-A6E5-72AC7F3CA169

Q46178252-B485FA50-0750-40EE-987E-95793ABD1B01

P304

Q46178252-EFDA701E-F8E9-4794-AA80-ADC484BCFA11

P31

Q46178252-B21F694A-3449-4A2B-B657-AF9E86C41FEC

P356

Q46178252-48FDEE2D-38AD-4516-A975-EBFEB705C18A

P407

Q46178252-8135D398-111B-455B-9ABD-B6715CE9759B

P433

Q46178252-A423241F-3F6E-41AB-9B25-7BECBFE83120

P478

Q46178252-B7EC21F2-69AD-4A81-BC93-02619441ED6A

P577

Q46178252-EAC403E2-93AA-405B-92E1-E05B098048FC

P5875

Q46178252-98253D6F-D895-486F-BE73-D5BA547A19A6

P698

Q46178252-622A03F4-FBE3-4BC8-812E-7FE22147F717

P921

Q46178252-DCBF028E-1FB7-45F4-BCB8-5893A1A7EC7B

P356

1078-0432.CCR-08-1253

P1433

Clinical Cancer Research

P1476

Mechanism and management of AKT inhibitor-induced hyperglycemia.

@en

P2093

Derek J Eberwein

http://www.w3.org/2001/XMLSchema#string

Gobalakrishnan Sundaresan

http://www.w3.org/2001/XMLSchema#string

Jason A Kahana

http://www.w3.org/2001/XMLSchema#string

Kathleen K Brown

http://www.w3.org/2001/XMLSchema#string

Ming-Chih Crouthamel

http://www.w3.org/2001/XMLSchema#string

Rakesh Kumar

http://www.w3.org/2001/XMLSchema#string

Shu-Yun Zhang

http://www.w3.org/2001/XMLSchema#string

Susan Korenchuk

http://www.w3.org/2001/XMLSchema#string

P304

217-225

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-1253

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23715251

http://www.w3.org/2001/XMLSchema#string

P698

19118049

http://www.w3.org/2001/XMLSchema#string

P921